Drugs.com - Clinical Trials

U.S. FDA Accepts Gilead’s New Drug Applications for Twice-Yearly Lenacapavir for HIV Prevention Under Priority Review

FOSTER CITY, Calif.--(BUSINESS WIRE) February 18, 2025 -- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) submissions for lenacapavir—the...

Feb 27, 2025 - 06:43
 0
U.S. FDA Accepts Gilead’s New Drug Applications for Twice-Yearly Lenacapavir for HIV Prevention Under Priority Review
FOSTER CITY, Calif.--(BUSINESS WIRE) February 18, 2025 -- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) submissions for lenacapavir—the...
Read More

Tags:

Previous Article

Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Pat...

Next Article

Innovent Receives Second Fast Track Designation from the U.S. FDA for IBI363 (PD...

Related Posts

Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis

Nektar Therapeutics Receives Fast Track Designation for...

Feb 10, 2025  0

Clarity Receives US FDA Fast Track Designation for the Treatment of Metastatic Castration-Resistant Prostate Cancer Patients with Cu-67 SAR-bisPSMA

Clarity Receives US FDA Fast Track Designation for the ...

Feb 20, 2025  0

Sapience Therapeutics Receives FDA Orphan Drug Designation for ST316, a First-in-Class β-catenin Antagonist, for the Treatment of Familial Adenomatous Polyposis (FAP)

Sapience Therapeutics Receives FDA Orphan Drug Designat...

Feb 9, 2025  0